Navigation Links
Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
Date:3/26/2008

, U.S. Phase II clinical trial evaluating the use of CPP-109 in treating patients with cocaine addiction. The Phase II trial is designed as a randomized, double-blind, placebo-controlled, intent-to-treat, multi-center trial to evaluate the safety and efficacy of CPP-109 as a treatment for cocaine addiction. Under the trial protocol, patients will be treated for a period of 12 weeks, with an additional 12 weeks of follow-up. The primary objective of the trial is to demonstrate that a larger proportion of CPP-109-treated subjects than placebo-treated subjects are cocaine-free during their last two weeks of treatment (weeks 11 and 12). Additionally, Catalyst will be measuring a number of secondary endpoints based on reductions of cocaine use and craving. Catalyst expects to initiate a similar trial in patients with methamphetamine addiction in the second quarter of 2008.

The Company expects to receive initial top-line results from its Phase II clinical trial for cocaine addiction in the fourth quarter of 2008. Top-line results of the trial for methamphetamine addiction are expected in the third quarter of 2009.

About Catalyst Pharmaceutical Partners, Inc.

Catalyst Pharmaceutical Partners is a biopharmaceutical company focused on the development and commercialization of prescription drugs for the treatment of addiction. The Company has obtained from Brookhaven National Laboratory an exclusive worldwide license for nine patents and four patents pending in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions. Catalyst has also been granted rights to Brookhaven's vigabatrin-related foreign patents or patents pending in more than 30 countries. The Company's initial product candidate is CPP-109, which is the Company's finished dosage form of vigabatrin, also referred to in the literature as gamma-vinyl-GABA or GVG. CPP-109 has been granted "Fast Track" status by the FDA for the treatment of cocaine add
'/>"/>

SOURCE Catalyst Pharmaceutical Partners
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) announces that ... to the announced tender offer for all of the outstanding shares ... of the waiver, the transaction is no longer conditional on OFT ... 24, 2014 following the currently scheduled expiration time, subject to the ...
(Date:1/15/2014)... , Jan. 15, 2014 Tegra Medical is very ... King as its new Chief Executive Officer.  Mark was ... which he has overseen the company,s four facilities in ... Costa Rica.  Mr. King joined Tegra Medical in 2012 with ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... & Forecast – Worldwide Analysis ... Pump Market Analysis ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17
(Date:4/17/2014)... MD, was recently invited to submit a review ... Microbiology , one of the world,s foremost scientific ... specialist, and chair of the Department of Pediatrics ... analyzed the epidemiology and microbiology of co-infections during ... as more recent 2009 novel H1N1 pandemic. ...
(Date:4/17/2014)... Il. (April 17, 2014) Doctors who treat ... called lymphangioleiomyomatosis (LAM) can face an agonizing treatment ... of the disease and help relieve shortness of ... transplants, and sirolimus can cause potentially fatal complications ... pulmonologist Dr. Daniel Dilling, medical director of Loyola ...
(Date:4/17/2014)... CHICAGO, IL, April 17, 2014-- Colic affects about one ... accounts for numerous pediatric visits during the first several ... of colic symptoms was showing promise; however, the April ... (BMJ2014;348:g2107; Sung, Valerie) reported on a study, "Probiotics ... probiotic L reuteri for infant colic ...
(Date:4/17/2014)... EcoHealth Alliance, a nonprofit organization that focuses on ... review today examining the current state of knowledge of ... for improved global surveillance strategies to combat the emergence ... Ebola in West Africa that has claimed the lives ... Liberia. According to the World Health Organization (WHO), ...
(Date:4/17/2014)... An international research team led by Cesar A. Arias, ... Center at Houston (UTHealth) has identified a new superbug ... The report appeared in the April 17 issue of ... The new superbug is part of a class of ... or MRSA, which is a major cause of hospital ...
Breaking Medicine News(10 mins):Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:New MRSA superbug emerges in Brazil 2
... But new poll shows two-thirds just accept it and do best ... Americans are working later and sleeping less, a dangerous combination which ... lack of interest in sex. , And while most people know ... about it, a new poll shows. , "People are actually acknowledging ...
... Awareness Week (March 2-8), the Association for Professionals in,Infection ... can take to become their own advocate and reduce ... Visit http://www.apic.org during Patient Safety Awareness ... Most people invest more time into selecting a ...
... OTTAWA, Canada, March 3 ,InterACTIVE Nutrition International ... Bulletin Board: NTNI) http://www.naturalnutritioninc.com has ... Nutrition,s Ottawa based,manufacturing facility, InterACTIVE Nutrition, Inc., ... of health conscious consumers in Iraq. The ...
... to raise awareness and advocate for affordable health coverage. ... ... DETROIT, March 3 Leaders from throughout Michigan,including representatives of insurers, ... supporters of the newly formed,Michigan Cover The Uninsured Network (MCTUN). The ...
... example of another,news article, in a respected outlet (Yahoo), ... need it is a good idea., (I,m not ... see this argument being presented by ,credible, members of ... news outlet.), This time, they,re* going after whether ...
... Smith & Nephew,Inc.,s (NYSE: SNN ; ... approval of its award winning OXINIUM(TM),oxidized zirconium technology., ... company to offer such a,revolutionary and award winning ... alloy with a ceramic bearing surface. OXINIUM,provides low ...
Cached Medicine News:Health News:Americans Sleepier Than Ever 2Health News:Americans Sleepier Than Ever 3Health News:APIC Issues Recommendations on How to Have a Healthy Hospital Stay 2Health News:Natural Nutrition Ships First InterACTIVE Nutrition Brand Products to Iraq 2Health News:Michigan Leaders Join Network to Push for Coverage of State's 1.4 Million Uninsured 2Health News:Putting an End to Medical Cruelty: A Horrifying Article in Yahoo this Week by T. L. Kittle 2Health News:Putting an End to Medical Cruelty: A Horrifying Article in Yahoo this Week by T. L. Kittle 3Health News:Smith & Nephew Wins OXINIUM(TM) Approval in Japan 2Health News:Smith & Nephew Wins OXINIUM(TM) Approval in Japan 3
Large, bright images from a bronchoscope designed for routine examination and treatment....
... the first in a series of bronchofiberscopes ... features necessary to meet the demand for ... scope includes a new control section and ... It also provides a wider field of ...
... Double lumen ... one-lung ventilation., ... Tube is packaged ... tube-to-circuit adaptors, suction ...
... Used for endobronchial blockade ... right lung for procedures ... The set consists of ... and an Arndt Multiport ...
Medicine Products: